Reuters logo
BRIEF-Cymabay to deliver interim results from ongoing phase 2 study of Seladelpar at AASLD 2017
October 9, 2017 / 12:18 PM / 2 months ago

BRIEF-Cymabay to deliver interim results from ongoing phase 2 study of Seladelpar at AASLD 2017

Oct 9 (Reuters) - Cymabay Therapeutics Inc

* Cymabay announces oral late-breaking presentation of interim results from an ongoing Phase 2 study of patients with primary biliary cholangitis at the AASLD 2017 Liver Meeting

* Cymabay Therapeutics - ‍interim Phase 2 study results demonstrate potential for superior efficacy, better tolerability over existing second-line therapy​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below